Mechanistic PK-PD model of alendronate treatment of postmenopausal osteoporosis predicts bone site-specific response

Alendronate is the most widely used drug for postmenopausal osteoporosis (PMO). It inhibits bone resorption, affecting osteoclasts. Pharmacokinetics (PK) and pharmacodynamics (PD) of alendronate have been widely studied, but few mathematical models exist to simulate its effect. In this work, we have...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvo-Gallego, José L., Pivonka, Peter, Ruiz-Lozano, Rocío, Martínez-Reina, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428150/
https://www.ncbi.nlm.nih.gov/pubmed/36061434
http://dx.doi.org/10.3389/fbioe.2022.940620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428150/
https://www.ncbi.nlm.nih.gov/pubmed/36061434
http://dx.doi.org/10.3389/fbioe.2022.940620

Ejemplares similares